Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CLB

CLB - Core Laboratories NV Stock Price, Fair Value and News

18.14USD-0.28 (-1.52%)Market Closed

Market Summary

CLB
USD18.14-0.28
Market Closed
-1.52%

CLB Stock Price

View Fullscreen

CLB RSI Chart

CLB Valuation

Market Cap

681.3M

Price/Earnings (Trailing)

28.73

Price/Sales (Trailing)

1.36

EV/EBITDA

13

Price/Free Cashflow

106.96

CLB Price/Sales (Trailing)

CLB Profitability

Free Cashflow Yield

0.93%

CLB Fundamentals

CLB Revenue

CLB Earnings

Breaking Down CLB Revenue

Last 7 days

1.4%

Last 30 days

8.5%

Last 90 days

30.6%

Trailing 12 Months

-23.4%

How does CLB drawdown profile look like?

CLB Financial Health

CLB Investor Care

Dividend Yield

0.27%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023502.8M000
2022477.2M479.3M487.3M489.7M
2021443.3M446.3M458.9M470.3M
2020651.4M598.1M530.3M487.3M
2019692.7M684.5M676.4M668.2M
2018000700.8M
2017000647.8M

Tracking the Latest Insider Buys and Sells of Core Laboratories NV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2023
temeng kwaku
acquired
-
-
5,485
-
Apr 01, 2023
straughen michael
sold (taxes)
-55,654
22.05
-2,524
-
Apr 01, 2023
klingensmith harvey robert
acquired
-
-
5,485
-
Apr 01, 2023
murray katherine
acquired
-
-
5,485
-
Apr 01, 2023
carnes martha z.
acquired
-
-
5,485
-
Apr 01, 2023
van dijken eeuwijk monique
acquired
-
-
5,485
-
Apr 01, 2023
straughen michael
acquired
-
-
5,485
-
Dec 31, 2022
hill christopher scott
sold (taxes)
-252,767
20.27
-12,470
svp & cfo
Dec 31, 2022
hill christopher scott
acquired
-
-
31,688
svp & cfo
Dec 31, 2022
bruno lawrence
sold (taxes)
-727,531
20.27
-35,892
chairman and ceo

1–10 of 50

Which funds bought or sold CLB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-837,031
-
-%
May 16, 2024
Pineridge Advisors LLC
sold off
-100
-1,695
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.23
-72,668
798,200
-%
May 16, 2024
Tidal Investments LLC
unchanged
-
-28,907
733,051
0.01%
May 16, 2024
COMERICA BANK
reduced
-10.33
-58,057
379,346
-%
May 15, 2024
GOLDMAN SACHS GROUP INC
reduced
-40.38
-1,088,200
1,481,900
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
reduced
-20.62
-663,483
2,192,510
-%
May 15, 2024
MARSHALL WACE, LLP
added
569
1,774,380
2,098,640
-%
May 15, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
8.44
715
15,355
-%
May 15, 2024
Royal Bank of Canada
added
0.31
-30,000
930,000
-%

1–10 of 45

Are Funds Buying or Selling CLB?

Are funds buying CLB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CLB
No. of Funds

Unveiling Core Laboratories NV's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 12, 2023
alger associates inc
0%
0
SC 13G/A
Feb 14, 2023
alger associates inc
8.3%
3,853,977
SC 13G/A
Feb 14, 2023
earnest partners llc
7.7%
3,573,101
SC 13G/A
Feb 14, 2023
ariel investments, llc
20.9%
9,703,122
SC 13G/A
Feb 09, 2023
vanguard group inc
11.35%
5,262,192
SC 13G/A
Jan 26, 2023
blackrock inc.
12.6%
5,848,677
SC 13G/A
Jan 20, 2023
blackrock inc.
12.6%
5,848,677
SC 13G/A
Feb 14, 2022
ariel investments, llc
16.9%
7,804,307
SC 13G/A
Feb 11, 2022
earnest partners llc
7.4%
3,433,430
SC 13G/A
Feb 09, 2022
vanguard group inc
10.73%
4,967,126
SC 13G/A

Peers (Alternatives to Core Laboratories NV)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
66.4B
-
-6.10% 0.93%
15.32
17.48
-86.47% 12.21%
32.2B
23.1B
-6.04% 18.97%
12.41
1.39
6.71% 32.21%
MID-CAP
10.9B
8.1B
0.12% 80.60%
51.4
1.34
18.75% 572.06%
7.2B
8.8B
-1.88% 17.53%
7.31
0.82
14.70% 198.19%
6.3B
3.7B
-6.73% 21.65%
17.19
1.68
-4.02% 100.20%
3.9B
4.6B
5.15% 77.56%
8.13
0.85
-1.29% -16.22%
3.1B
1.0B
1.28% 108.33%
23.9
3
17.17% 118.50%
SMALL-CAP
1.5B
2.3B
-1.24% 48.40%
6.48
0.67
2.36% 81.92%
681.3M
-
8.54% -23.41%
28.73
1.36
- -
642.6M
443.5M
-3.72% -23.05%
-29.63
1.45
19.98% -325.36%
344.8M
386.1M
17.68% 82.03%
-36.38
0.89
9.26% 57.09%
264.0M
701.7M
-21.74% -26.57%
10.31
0.38
0.29% 55.69%

Core Laboratories NV News

Latest updates
Yahoo Lifestyle UK17 May 202412:39 pm
Yahoo Lifestyle UK15 May 202405:37 am
Yahoo Canada Shine On10 May 202402:51 pm

Core Laboratories NV Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42017Q4
Revenue0.6%128128126121115125118119108114105116152157173169169--
EBITDA Margin8.0%0.13*0.12*0.12*0.10*0.11*0.14*0.16*0.18*0.14*----------
Interest Expenses11.3%3.003.003.003.003.003.003.003.001.003.005.003.003.004.004.004.004.004.00-
Income Taxes-89.7%1.006.004.002.00-1.209.003.002.002.007.004.00-0.26-4.007.003.005.00-27.616.00-
Earnings Before Taxes-75.6%3.0013.0012.009.00-3.0012.004.0010.0010.0020.007.00-5.90-11217.0028.0024.0013.0014.00-
EBT Margin17.2%0.07*0.06*0.06*0.04*0.05*0.08*0.10*0.11*0.07*----------
Net Income-64.8%2.007.008.007.00-1.893.001.008.008.0014.003.00-5.72-10810.0024.0027.0041.009.00-
Net Income Margin18.7%0.05*0.04*0.03*0.02*0.02*0.04*0.07*0.07*0.04*----------
Free Cashflow-148.0%-5.3811.003.00-2.593.002.009.007.005.00----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42017Q4
Assets2.6%594578570578585581586598584569591614647775788782792649585
  Current Assets7.7%228212195200202189187201186166170191220221---231-
    Cash Equivalents5.6%16.0015.0014.0016.0022.0018.0019.0034.0028.0014.0015.0021.0014.0011.0013.0013.0013.0013.0014.00
  Inventory11.4%67.0060.0055.0053.0048.0045.0044.0039.0039.0038.0043.0042.0052.0050.00---46.00-
  Net PPE-2.6%102105107109110111113112113115117120123124---123123
  Goodwill0%99.0099.0099.0099.0099.0099.0099.0099.0099.0099.0099.0099.0099.00213---219179
  Current Liabilities-7.3%96.0010387.0096.0010091.0093.0091.0086.0090.0017299.00108112---103-
  Long Term Debt4.7%180172183187190189188208208259190287302305---290-
Shareholder's Equity6.0%19518417917416616116115414676.0072.0066.0070.00182195192187161149
  Retained Earnings2.2%88.0086.0080.0073.0066.0068.0066.0066.0058.0050.0037.0035.0041.00161---156-
  Additional Paid-In Capital8.8%11110210610510710110698.0010341.0061.0061.0061.0052.00---57.00-
Accumulated Depreciation0.1%315315313310307306305301-294---------
Shares Outstanding0.0%47.0047.0046.0046.0046.0046.0046.0046.0045.0044.0044.0044.00-------
Minority Interest1.5%5.005.005.005.005.005.004.004.004.004.004.004.004.004.00---4.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42017Q4
Cashflow From Operations-124.0%-3,16913,2115,8506055,2907,15411,9529,4867,987-11,84620,69326,99622,02521,30225,98917,08025,156--
  Share Based Compensation2855.3%8,9843042,234-1,0096,2272,4478,5603,6814,405-8,8602,8592,86510,53013,7003,3117,1417,2009,900-
Cashflow From Investing-292.6%-2,0381,058-2,557-2,785428-3,694-3,151-2,308-1,07017,381-2,374-3,272-3,884-5,134-7,59712,259-5,205--
Cashflow From Financing148.2%6,064-12,573-5,709-3,709-1,384-4,807-23,368-1,3677,083-6,875-24,131-16,656-15,343-18,204-17,810-29,999-19,861--
  Dividend Payments0.4%46646446346346346246346344644544544511,11124,40624,39924,39524,374--
  Buy Backs-99.9%1.001,6151452001,9204,3452,8808601711,2001571981,2381,806411604487--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CLB Income Statement

2023-03-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
REVENUES:  
Revenue$ 128,356$ 115,300
OPERATING EXPENSES:  
General and administrative expense, exclusive of depreciation expense shown below16,33112,545
Depreciation3,9394,384
Amortization105173
Other (income) expense, net(28)1,637
OPERATING INCOME (LOSS)6,481(391)
Interest expense3,4292,644
Income (loss) before income taxes3,052(3,035)
Income tax expense (benefit)610(1,196)
Net income (loss)2,442(1,839)
Net income (loss) attributable to non-controlling interest6949
Net income (loss) attributable to Core Laboratories N.V.$ 2,373$ (1,888)
EARNINGS (LOSS) PER SHARE INFORMATION:  
Basic earnings (loss) per share$ 0.05$ (0.04)
Basic earnings (loss) per share attributable to Core Laboratories N.V.0.05(0.04)
Diluted earnings (loss) per share0.05(0.04)
Diluted earnings (loss) per share attributable to Core Laboratories N.V.$ 0.05$ (0.04)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:  
Basic46,63446,298
Diluted47,48146,298
Service [Member]  
REVENUES:  
Revenue$ 91,076$ 84,723
OPERATING EXPENSES:  
Cost of services and product sales exclusive of depreciation expense shown below70,93468,857
Product [Member]  
REVENUES:  
Revenue37,28030,577
OPERATING EXPENSES:  
Cost of services and product sales exclusive of depreciation expense shown below$ 30,594$ 28,095

CLB Balance Sheet

2023-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 16,285$ 15,428
Accounts receivable, net of allowance for credit losses of $2,436 and $2,214 at 2023 and 2022, respectively110,699106,913
Inventories67,34260,445
Prepaid expenses13,19715,665
Income taxes receivable13,7818,190
Other current assets6,6235,061
TOTAL CURRENT ASSETS227,927211,702
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $315,027 and $314,737 at 2023 and 2022, respectively102,341105,028
RIGHT OF USE ASSETS56,66352,379
INTANGIBLES, net of accumulated amortization and impairment of $17,650 and $17,475 at 2023 and 2022, respectively7,2687,483
GOODWILL99,44599,445
DEFERRED TAX ASSETS, net67,02568,570
OTHER ASSETS32,94833,747
TOTAL ASSETS593,617578,354
CURRENT LIABILITIES:  
Accounts payable38,36645,847
Accrued payroll and related costs23,48423,431
Taxes other than payroll and income3,6904,822
Unearned revenues5,9525,942
Operating lease liabilities11,07311,699
Income taxes payable5,1333,034
Other current liabilities7,9268,360
TOTAL CURRENT LIABILITIES95,624103,135
LONG-TERM DEBT, net180,440172,386
LONG-TERM OPERATING LEASE LIABILITIES43,79338,305
DEFERRED COMPENSATION29,77231,814
DEFERRED TAX LIABILITIES, net22,26822,877
OTHER LONG-TERM LIABILITIES21,56920,883
COMMITMENTS AND CONTINGENCIES
EQUITY:  
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding00
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 46,701,102 issued and 46,634,027 outstanding at 2023 and 46,699,102 issued and 46,631,934 outstanding at 20221,1941,194
Additional paid-in capital111,235102,254
Retained earnings87,85585,949
Accumulated other comprehensive income (loss)(3,538)(3,777)
Treasury shares (at cost), 67,075 at 2023 and 67,168 at 2022(1,360)(1,362)
Total Core Laboratories N.V. shareholders' equity195,386184,258
Non-controlling interest4,7654,696
TOTAL EQUITY200,151188,954
TOTAL LIABILITIES AND EQUITY$ 593,617$ 578,354
CLB
Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, hydrogen storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. The company was founded in 1936 and is based in Houston, Texas.
 CEO
 WEBSITEcorelab.com
 INDUSTRYOil - Services
 EMPLOYEES3600

Core Laboratories NV Frequently Asked Questions


What is the ticker symbol for Core Laboratories NV? What does CLB stand for in stocks?

CLB is the stock ticker symbol of Core Laboratories NV. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Core Laboratories NV (CLB)?

As of Wed May 22 2024, market cap of Core Laboratories NV is 681.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLB stock?

You can check CLB's fair value in chart for subscribers.

What is the fair value of CLB stock?

You can check CLB's fair value in chart for subscribers. The fair value of Core Laboratories NV is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Core Laboratories NV is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Core Laboratories NV a good stock to buy?

The fair value guage provides a quick view whether CLB is over valued or under valued. Whether Core Laboratories NV is cheap or expensive depends on the assumptions which impact Core Laboratories NV's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLB.

What is Core Laboratories NV's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, CLB's PE ratio (Price to Earnings) is 28.73 and Price to Sales (PS) ratio is 1.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Core Laboratories NV's stock?

In the past 10 years, Core Laboratories NV has provided -0.184 (multiply by 100 for percentage) rate of return.